Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan

Asia-Pacific Journal of Clinical Oncology

Volumn 7, Issue SUPPL.2, 2011, Pages 22-33

  Ahn, Myung Ju ^a   Tsai, Chun Ming ^g   Hsia, Te Chun ^h   Wright, Elaine ^e   Chang, John Wen Cheng ⁱ   Kim, Heung Tae ^f   Kim, Joo Hang ^b   Kang, Jin Hyoung ^c   Kim, Sang We ^d   Bae, Eun Jin ^e   Kang, Mijeong ^e   Lister, Johanna ^j   Walzer, Stefan ^e  

^a Samsung Medical Center   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e Roche Korea Co Ltd   (South Korea)

^f National Cancer Center   (South Korea)

^g TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^h CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

ⁱ CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^j Analytica International Inc   (Germany)

more..

Author keywords

Antineoplastic combined chemotherapy protocol; Asia; Bevacizumab; Cost benefit analysis; Non small cell lung carcinoma

Indexed keywords

BEVACIZUMAB; CISPLATIN; GEMCITABINE; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HEALTH ECONOMICS; HEALTH STATUS; HUMAN; KOREA; LIFE EXPECTANCY; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSITIVITY ANALYSIS; TAIWAN;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; GLUTAMATES; GUANINE; HUMANS; KOREA; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TAIWAN;

EID: 79956084960     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2011.01399.x     Document Type: Article

References (65)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. International Agency for Research on Cancer, Lyon, France 2008. Lung cancer incidence and mortality worldwide in 2008 Summary [cited 14 April 2011]. Available from: .
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. International Agency for Research on Cancer, Lyon, France 2010. Estimated cancer incidence, all ages in Republic of Korea for both sexes [cited 14 April 2011]. Available from: .
3. Ferlay J, Shin HR, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. 1st edn. International Agency for Research on Cancer. Lyon, France 2010. Estimated cancer mortality, all ages in Republic of Korea for both sexes [cited 14 April 2011]. Available from: .
4. Ferlay J, Shin HR, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide:IARC CancerBase No. 10 [Internet]. International Agency for Research on Cancer, Lyon, France 2010. Estimated cancer incidence and mortality, all ages in Taiwan for both sexes [cited 14 April 2011]. Available from: .
5. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710-7.
6. SEER Cancer. Statistics review 1957-2007. [Internet]. National Cancer Institute 2011. [Cited 14 April 2011 Available from: .
7. Gridelli C, Maione P, Rossi A, De MF. The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments. Oncologist 2007; 12: 1183-93.
8. Wu YL, Zhou Q. Lung cancer management in the Asia-Pacific region: what's the difference compared with the United States and Europe? Results of the Second Asia Pacific Lung Cancer Conference. J Thorac Oncol 2007; 2: 574-6.
9. Mok T, Hsia T-C, Tsai C-M etal. Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: A substudy of the Avastin in Lung trial. Asia-Pac J Clin Oncol 2011; 7(Suppl. 2): 4-12.
10. Yang CH, Simms L, Park K, Lee JS, Scagliotti G, Orlando M. Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial. J Thorac Oncol 2010; 5: 688-95.
11. NCCN-KOREA Non-Small Cell Lung Cancer Panel. NCCN clinical practice guidelines in oncology: non-small cell lung cancer. Korean guidelines V.2.2008. [Internet]. National Comprehensive Cancer Network & EMD Scientific Communication Group 2009 [cited 2 Nov 2011.] Available from:
12. NCCN Non-Small Cell Lung Cancer USA. NCCN clinical practice guidelines in oncology: non-small cell lung cancer V.3.2011. National Comprehensive Cancer Network 2011 [cited 14 April 2011.] Available from:
13. NCCN Asia Consensus Panel NSCLC. NCCN clinical practice guidelines in oncology: Asia consensus statement: non-small cell lung cancer V.1.2009. National Comprehensive Cancer Network 2009 [Cited 2 Nov 2011.] Available from:
14. Bordeleau L. Pharmacoeconomics of systemic therapies for lung cancer. Treat Respir Med 2006; 5: 129-41.
15. Carlson JJ, Veenstra DL, Ramsey SD. Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer. Drugs 2008; 68: 1105-13.
16. Giuliani G, Grossi F, De Marinis F, Walzer S. Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy. Lung Cancer 2010; 69: S11-S17.
17. Bischoff HG, Heigener DF, Walzer S, Nuijten M. Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany. Lung Cancer 2010; 69: Suppl 1: S18-S23.
18. National Institute for Health and Clinical Excellence. Pemetrexed for the first-line treatment of non-small-cell lung cancer [TA181]. National Institute for Health and Clinical Excellence, London 2009. Report No.: TA181.
19. National Institute for Health and Clinical Excellence. Erlotinib for the treatment of non-small cell lung cancer [TA162]. National Institute for Health and Clinical Excellence, London 2010. Report No.: TA162.
20. National Institute for Health and Clinical Excellence. Pemetrexed for the treatment of non-small cell lung cancer [TA124]. National Institute for Health and Clinical Excellence, London. 2007. Report No.: TA124.
21. Health Insurance Review Agency. Pharmaceutical economic evaluation guidelines (January 2006) [in Korean]. ISPOR, Pharmacoeconomic guidelines around the world ©2011 International Society for Pharmacoeconomics and Outcomes Research 2011 [cited 14 April 2011.] Available from:
22. Financial Times currency conversion rates. Financial Times 2011 [Cited 2 March 2011.] Available from:
23. Canadian Agency for Drugs and Technology in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada[3rd edn]. CADTH, Ottowa 2006.
24. Ramsey SD. Is there an international backlash against cost-utility analysis? President's message. ISPOR Connections 2010; 16 (6): 3.
25. Chang JW-C, Thongprasert S, Wright E etal. An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia. Asia-Pac J Clin Oncol 2011; 7(Suppl. 2): 13-21.
26. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50: 683-91.
27. Scagliotti GV, Parikh P, von PJ etal. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-51.
28. Health Insurance Review Agency. Weighted average price per components of drugs. Health Insurance Review Agency, Seoul, Republic of Korea. 2009 [in Korean]
29. Health Insurance Review Agency. General treatment principals for antiemetics. Health Insurance Review Agency, Seoul, Republic of Korea. 2009 [in Korean]
30. Bureau of National Health Insurance. Pharmaceutical benefits scheme. Bureau of National Health Insurance, Taipei, Taiwan. 2009 [in Chinese]
31. Health Insurance Review Agency. Medical insurance fee files. Health Insurance Review Agency, Seoul, Republic of Korea. 2009 [in Korean]
32. Health Insurance Review Agency. Lung cancer treatment record. Health Insurance Review Agency, Seoul, Republic of Korea. 2009 [in Korean]
33. Kim SY, Kim SG, Park JH, Park EC. [Costs of initial cancer care and its affecting factors. J Prev Med Public Health 2009; 42: 243-50. (in Korean.)
34. Health Insurance Review Agency. Cost statistics. Health Insurance Review Agency, Seoul, Republic of Korea. 2009 [in Korean]
35. National Health Insurance Corporation. Survey of medical expences of patient's charge. National Health Insurance Corporation (NHCI), Seoul, Republic of Korea. 2008 [in Korean]
36. Obasaju CK, Raju RN, Stinchcombe T etal. Final results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) ± enzastaurin (E) versus docetaxel (D) + Cb as first-line treatment of patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). 2009. J Clin Oncol 27:15s (abstr. 80370).
37. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 1993; 11: 1866-72.
38. Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest 1994; 106: 861-5.
39. Fidias P, Novello S. Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 5116-23.
40. Lustberg MB, Edelman MJ. Optimal duration of chemotherapy in advanced non-small cell lung cancer. Curr Treat Options Oncol 2007; 8: 38-46.
41. Lima JP, dos Santos LV, Sasse EC, Sasse AD. Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: a systematic review with meta-analysis. Eur J Cancer 2009; 45: 601-7.
42. Larsen H, Sorensen JB, Nielsen AL, Dombernowsky P, Hansen HH. Evaluation of the optimal duration of chemotherapy in phase II trials for inoperable non-small-cell lung cancer (NSCLC). Ann Oncol 1995; 6: 993-7.
43. Smith IE, O'Brien ME, Talbot DC etal. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001; 19: 1336-43.
44. FDA. Bevacizumab (Avastin) label information [Internet]. U.S. Food and Drug Administration. 2011 [cited 2 Jan 2011.] Available from: .
45. L'Institut National du Cancer. Recommandations professionnelles: Cancer du poumon non à petites cellules. INCa, Boulogne-Billancourt 2010.
46. Bevacizumab: cancer drug information. [Internet]. National Cancer Institute (NCI) US. 2011. [updated 4 April 2011, cited 14 April, 2011] Available from: .
47. Department of Health and Ageing: Australian public assessment report for bevacizumab. Therapeutic Goods Administration, Australian Government 2010 [cited 14 April, 2011] Available from: .
48. Silvestrini, R. Basi Scientifiche Linea Guida: Carcinoma Non a Piccole Cellule [in Italian]. [Internet]. Instituto Superiore di Sanità (ISS) ©- Alleanza Contro il Cancro 2011 [cited 3 Jan 2011.] Available from: .
49. Goeckenjan G, Sitter H, Thomas M etal. Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society. Pneumologie 2011; 65: 39-59.
50. Eichhorn M, Kleespies A, Angele MK, Jauch K, Bruns C. Angiogenesis in cancer: molecular mechanisms, clinical impact. Langenbecks Arch Surg 2007; 392: 371-9.
51. Veeravagu A, Hsu AR, Cai W, Hou LC, Tse VC, Chen X. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy. Recent Pat Anticancer Drug Discov 2007; 2: 59-71.
52. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005; 15: 102-11.
53. Inai T, Mancuso M, Hashizume H etal. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004; 165: 35-52.
54. Erber R, Thurnher A, Katsen AD etal. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004; 18: 338-40.
55. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64: 3731-6.
56. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
57. Lee CG, Heijn M, di TE etal. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000; 60: 5565-70.
58. Willett CG, Boucher Y, di Tomaso E etal. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-7.
59. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005; 65: 671-80.
60. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995; 95: 1789-97.
61. Hope T, Savulescu J, Hendrick J. Medical Ethics and Law: The Core Curriculum. Churchill Livingstone, Edinburgh 2003.
62. Normand C. Measuring outcomes in palliative care: limitations of QALYs and the road to PalYs. J Pain Symptom Manage 2009; 38: 27-31.
63. Park YS, Kim SH, Park SK etal. Costs for 5-year lung cancer survivors in a tertiary care hospital in South Korea. Lung Cancer 2010; 68: 299-304.
64. Kim YA, Yun Y, Zo JI. Employment status and work-related difficulties in lung cancer survivors compared with general population. 2010. ISPOR 13th Annual European Congress; Prague, Czech Republic, Nov 6-9, 2010, Poster PCN137.
65. Ohguri T, Narai R, Funahashi A etal. Limitations on work and attendance rates after employees with cancer returned to work at a single manufacturing company in Japan. JOccup Health 2009; 51: 267-72.